USNA Usana Health Sciences Inc

Price (delayed)

$74.26

Market cap

$1.42B

P/E Ratio

13.55

Dividend/share

N/A

EPS

$5.48

Enterprise value

$1.2B

USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25 ...

Highlights
The price to earnings (P/E) is 28% lower than the 5-year quarterly average of 18.9 and 12% lower than the last 4 quarters average of 15.4
USNA's net income is down by 16% year-on-year and by 7% since the previous quarter
The EPS has contracted by 11% YoY and by 5% from the previous quarter

Key stats

What are the main financial stats of USNA
Market
Shares outstanding
19.19M
Market cap
$1.42B
Enterprise value
$1.2B
Valuations
Price to earnings (P/E)
13.55
Price to book (P/B)
3.68
Price to sales (P/S)
1.25
EV/EBIT
7.5
EV/EBITDA
6.58
EV/Sales
1.04
Earnings
Revenue
$1.15B
EBIT
$159.68M
EBITDA
$181.99M
Free cash flow
$108.32M
Per share
EPS
$5.48
Free cash flow per share
$5.6
Book value per share
$20.18
Revenue per share
$59.5
TBVPS
$27.14
Balance sheet
Total assets
$572.92M
Total liabilities
$182.97M
Debt
$10M
Equity
$389.95M
Working capital
$205.82M
Liquidity
Debt to equity
0.03
Current ratio
2.3
Quick ratio
1.51
Net debt/EBITDA
-1.25
Margins
EBITDA margin
15.8%
Gross margin
81.6%
Net margin
9.4%
Operating margin
13.8%
Efficiency
Return on assets
18.7%
Return on equity
27%
Return on invested capital
123.3%
Return on capital employed
38.5%
Return on sales
13.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
0.65%
1 week
5.27%
1 month
8.76%
1 year
-27.17%
YTD
-26.62%
QTD
-6.53%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$1.15B
Gross profit
$939.73M
Operating income
$159.06M
Net income
$108.35M
Gross margin
81.6%
Net margin
9.4%
USNA's net income is down by 16% year-on-year and by 7% since the previous quarter
USNA's net margin is down by 14% YoY and by 4.1% from the previous quarter
The operating income has declined by 12% year-on-year and by 7% since the previous quarter
Usana Health Sciences's operating margin has decreased by 10% YoY and by 3.5% QoQ

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
P/E
13.55
P/B
3.68
P/S
1.25
EV/EBIT
7.5
EV/EBITDA
6.58
EV/Sales
1.04
The price to earnings (P/E) is 28% lower than the 5-year quarterly average of 18.9 and 12% lower than the last 4 quarters average of 15.4
The EPS has contracted by 11% YoY and by 5% from the previous quarter
USNA's P/B is 25% below its 5-year quarterly average of 4.9 and 20% below its last 4 quarters average of 4.6
The company's equity fell by 3.2% YoY
USNA's price to sales (P/S) is 26% less than its 5-year quarterly average of 1.7 and 22% less than its last 4 quarters average of 1.6
USNA's revenue is down by 3% since the previous quarter and by 2.1% year-on-year

Efficiency

How efficient is Usana Health Sciences business performance
The company's return on invested capital fell by 27% YoY and by 8% QoQ
The ROE has contracted by 17% YoY and by 6% from the previous quarter
Usana Health Sciences's ROA has decreased by 16% YoY and by 7% from the previous quarter
The ROS has contracted by 11% YoY and by 3.5% from the previous quarter

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The quick ratio has contracted by 11% YoY
The current ratio has decreased by 7% YoY
USNA's debt is 97% less than its equity
The company's equity fell by 3.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.